1 / 20

NYSE : WAG

NYSE : WAG. April 29 th , 2014 Leiyi (Sally) Huang Qun (Jett) Yu Siyang (Sylvia) Zhang. Agenda. Introduction Business Overview Stock Performance Financial Ratio Analysis Valuation Recommendation. Current Position. 500 shares bought on Oct 6, 1999 @ $25.00

darby
Télécharger la présentation

NYSE : WAG

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NYSE:WAG April 29th, 2014 Leiyi (Sally) Huang Qun (Jett) Yu Siyang (Sylvia) Zhang

  2. Agenda • Introduction • Business Overview • Stock Performance • Financial Ratio Analysis • Valuation • Recommendation

  3. CurrentPosition • 500 shares bought on Oct 6, 1999 @ $25.00 • CurrentStockPrice: $67.72(April25th2014) • LastAction:Sold200 out of 500shares in our portfolio • Unrealizedannualrateofreturn : 7.08%

  4. Company Overview • Pharmacies&DrugStore • MarketCapitalization:$63.61billion

  5. Industry Overview • MajorPlayers:CVSCaremark,RiteAidCorp • MacroeconomicForces: • Per capita disposable income • Populationaging • Healthcarereform • Unemploymentrate Sourcefromadministrationofaging,IBISWorld Business

  6. Porter’s Five Forces

  7. Strategic Alliance w. Alliance Boots • Currently45%ownershipinAllianceBoots • EntryandexpansiontoEuropeanMarket • Fullcombinationoption available in 2015

  8. Strategic Alliance w. AmerisourceBergen • 10-yearpharmaceuticalsupplyagreement • ABactastheprimarywholesaledistributionsource • AllthebrandedprescriptiondrugandsignificantportionofgenericdrugbusinesstransitionedtoAB

  9. SWOT Analysis

  10. Stock Performance

  11. Ratio Analysis

  12. Ratio Analysis

  13. Comparable Companies

  14. Comparable Company Analysis

  15. WACC Calculation

  16. Discounted Cash Flow Analysis

  17. Discounted Cash Flow Analysis

  18. Sensitivity Table

  19. Implied Price

  20. Recommendation • Sell 200 shares at market • 500 shares bought on Oct 6, 1999 @ $25.00 • CurrentStockPrice: $67.72(April25th2014) • Gain: $8544 Sell

More Related